Thalidomide

10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al.
5:47
Toxicities of MM drug treatments
Ravi Vij
10:42
Highlights from IMW 2019 Part I
Francesca Gay et al.
2:21
MM: BTD plus a monoclonal antibody
Amrita Krishnan
2:03
Myeloma XI: Gareth Morgan update
Gareth Morgan
2:12
Myeloma: immunomodulatory therapy and CHIP
Tarek H Mouhieddine
1:45
Treating MM: the European strategy
Enrique Ocio
6:09
Induction in myeloma: a journey over time
Mohamad Mohty
5:40
Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd
Philippe Moreau
2:45
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
4:35
Cereblon pathway-mediated IMiD resistance in multiple myeloma
Constantine Mitsiades
4:57
150 years of multiple myeloma therapy
Robert Kyle
1:44
Improved survival in MM with thalidomide before and after ASCT
Niels van de Donk
2:22
Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
Graham Jackson
1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals